PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19457609-3 2009 In this study, we showed that via STAT3 signaling, IFN-beta suppressed the proliferation, self-renewal, and tumorigenesis of GICs, induced their terminal differentiation to mature oligodendroglia-like cells, and exhibited synergistic cytotoxicity with temozolomide. Temozolomide 252-264 interferon beta 1 Homo sapiens 51-59 19267105-1 2008 Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide. Temozolomide 203-215 interferon beta 1 Homo sapiens 0-15 19513561-0 2009 Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Temozolomide 51-63 interferon beta 1 Homo sapiens 10-18 19513561-10 2009 Furthermore, significant amounts of endogenous IFN-beta protein were detected in TMZ-treated T98G cells by ELISA. Temozolomide 81-84 interferon beta 1 Homo sapiens 47-55 19513561-11 2009 These results suggest that the clinical therapeutic efficacy of TMZ might be improved by a combination with IFN-beta in malignant gliomas unmethylated at the MGMT gene. Temozolomide 64-67 interferon beta 1 Homo sapiens 108-116 19056675-0 2008 IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Temozolomide 63-75 interferon beta 1 Homo sapiens 0-8 19056675-2 2008 We hypothesized that IFN-beta could sensitize neuroblastoma cells to the cytotoxic effects of temozolomide through its ability to down-regulate MGMT expression. Temozolomide 94-106 interferon beta 1 Homo sapiens 21-29 19056675-8 2008 IFN-beta appears to sensitize neuroblastoma cells to the cytotoxic effects of temozolomide through attenuation of MGMT expression. Temozolomide 78-90 interferon beta 1 Homo sapiens 0-8 19267105-5 2008 Administration of interferon beta might have a favorable effect on tectal gliomas that are immunopositive for MGMT and resistant to chemoradiotherapy including temozolomide. Temozolomide 160-172 interferon beta 1 Homo sapiens 18-33 17683572-0 2007 Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. Temozolomide 78-90 interferon beta 1 Homo sapiens 17-32 17564708-2 2008 In our previous experiments, we observed that IFN-beta sensitized TMZ-resistant glioma cells with the unmethylated MGMT promoter and that the mechanism of action was possibly due to attenuation of MGMT expression via induction of TP53. Temozolomide 66-69 interferon beta 1 Homo sapiens 46-54 17564708-9 2008 In this context, IFN-beta inactivates MGMT via p53 gene induction and enhances the therapeutic efficacy to TMZ. Temozolomide 107-110 interferon beta 1 Homo sapiens 17-25 17683572-5 2007 Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ. Temozolomide 30-33 interferon beta 1 Homo sapiens 124-139 17683572-11 2007 CONCLUSION: It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy. Temozolomide 83-86 interferon beta 1 Homo sapiens 34-49 17683572-11 2007 CONCLUSION: It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy. Temozolomide 143-146 interferon beta 1 Homo sapiens 34-49 28387596-5 2017 These effects are more obvious when combining IFN-beta with classical antitumor therapies such as temozolamide, an oral chemotherapeutic, for both newly diagnosed and recurrent gliomas. Temozolomide 98-110 interferon beta 1 Homo sapiens 46-54 16838652-4 2006 For example, as a fundamental study, temozolomide is an enthusiastic chemodrug to enhance the anti-tumor effect of interferon-beta when it is combined, pre-clinical and clinical trial will be scheduled. Temozolomide 37-49 interferon beta 1 Homo sapiens 115-130 16140920-0 2005 IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Temozolomide 104-116 interferon beta 1 Homo sapiens 0-8 16140920-4 2005 Here, we show that IFN-beta sensitizes glioma cells that harbor the unmethylated MGMT promoter and are resistant to temozolomide. Temozolomide 116-128 interferon beta 1 Homo sapiens 19-27 16140920-6 2005 Our study suggests that clinical efficacy of temozolomide might be improved by combination with IFN-beta using appropriate doses and schedules of administration. Temozolomide 45-57 interferon beta 1 Homo sapiens 96-104 30864696-0 2019 Interferon-beta sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. Temozolomide 61-73 interferon beta 1 Homo sapiens 0-15 30864696-10 2019 We also demonstrated that a combination of TMZ and IFN-beta enhanced apoptosis and autophagy more efficiently compared with TMZ treatment alone. Temozolomide 124-127 interferon beta 1 Homo sapiens 51-59 22277391-5 2011 Previously, we demonstrated that Interferon-beta (IFN-beta) markedly enhanced chemosensitivity to TMZ in an in vitro study of human glioma cells; this finding suggested that one of the major mechanisms by which IFN-beta enhances chemosensitivity is the downregulation of MGMT transcription via p53 induction. Temozolomide 98-101 interferon beta 1 Homo sapiens 33-48 22277391-5 2011 Previously, we demonstrated that Interferon-beta (IFN-beta) markedly enhanced chemosensitivity to TMZ in an in vitro study of human glioma cells; this finding suggested that one of the major mechanisms by which IFN-beta enhances chemosensitivity is the downregulation of MGMT transcription via p53 induction. Temozolomide 98-101 interferon beta 1 Homo sapiens 50-58 22277391-5 2011 Previously, we demonstrated that Interferon-beta (IFN-beta) markedly enhanced chemosensitivity to TMZ in an in vitro study of human glioma cells; this finding suggested that one of the major mechanisms by which IFN-beta enhances chemosensitivity is the downregulation of MGMT transcription via p53 induction. Temozolomide 98-101 interferon beta 1 Homo sapiens 211-219 21805051-3 2011 Recently, a synergistic antitumor effect between TMZ and interferon-beta (IFN-beta) was reported in malignant glioma cells. Temozolomide 49-52 interferon beta 1 Homo sapiens 74-82 21805051-8 2011 We present a list of the most highly upregulated and downregulated genes which may be involved in conferring a response to IFN-beta and synergistic effect between IFN-beta and TMZ in malignant gliomas. Temozolomide 176-179 interferon beta 1 Homo sapiens 123-131 27979804-0 2016 Correction: IFN-beta Down-Regulates the Expression of DNA Repair Gene MGMT and Sensitizes Resistant Glioma Cells to Temozolomide. Temozolomide 116-128 interferon beta 1 Homo sapiens 12-20 26171205-0 2015 Interferon-beta and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas. Temozolomide 57-69 interferon beta 1 Homo sapiens 0-15 22912934-4 2012 Previous studies have shown that a variety of drugs such as interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. Temozolomide 175-178 interferon beta 1 Homo sapiens 60-75 22912934-4 2012 Previous studies have shown that a variety of drugs such as interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. Temozolomide 175-178 interferon beta 1 Homo sapiens 77-85 21327711-1 2011 Our previous study demonstrated that interferon-beta markedly enhanced chemosensitivity to temozolomide; one of the major mechanisms is downregulation of O(6)-methylguanine DNA-methyltransferase transcription via p53 induction. Temozolomide 91-103 interferon beta 1 Homo sapiens 37-52 21472719-6 2011 The median survival time (MST) of the patients who received the combination of IFN-beta and TMZ was significantly greater with 19.9 months as compared to the TMZ alone group (12.7 months). Temozolomide 158-161 interferon beta 1 Homo sapiens 79-87 21472719-7 2011 Notably, in even patients whose tumors had unmethylated MGMT promoter, the MST prolonged to 17.2 months when receiving TMZ with IFN-beta, compared to 12.5 months in those receiving TMZ without IFN-beta. Temozolomide 119-122 interferon beta 1 Homo sapiens 128-136